Michael May | CEO
Centre for Commercialisation of Regenerative Medicine (CCRM)

Michael May is currently the Chief Executive Officer of the Centre for Commercialization of Regenerative Medicine (CCRM) a Canadian, federally incorporated, not-for-profit organization dedicated to supporting the development of foundational technologies that accelerate the commercialization of stem cell – and biomaterials – based technologies. Prior to CCRM, Michael was the President, and co-founder of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity. Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship in recognition of company creation from academic discovery. Michael sits on a number of Boards and advisory committees including: MaRS Innovation, 20/20 Vision a centre of excellence for biomaterials in ophthalmology, the Biozone and Bioproducts + Enzymes from Environmental Metagenomes Commercialization committee and the Department of Chemical Engineering and Applied Chemistry, at the University of Toronto.